View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
A drug to help restore bowel function in patients with opioid-induced constipation has received FDA approval. Methylnaltrexone bromide (Relistor) is indicated for patients with advanced illness who are receiving palliative care and who haven't responded sufficiently to laxatives.
Opioids interfere with bowel function by decreasing peristalsis. Given by subcutaneous injection, methylnaltrexone counteracts the constipating effects of opioids in the gastrointestinal (GI) tract without affecting opioid-mediated analgesic effects in the central nervous system.
The recommended starting schedule is one dose every other day. Patients should receive no more than one dose every 24 hours. Common adverse reactions include abdominal pain, gas, nausea, dizziness, and diarrhea. The drug is contraindicated in patients with known or suspected mechanical GI obstruction. For more information, visit http://www.relistor.com.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top